Palmedo Holger, Hensel Jenne, Reinhardt Michael, Von Mallek Dirk, Matthies Alexander, Biersack Hans Jürgen
Department of Nuclear Medicine, University of Bonn, Bonn, Germany.
Nucl Med Biol. 2002 Nov;29(8):809-15. doi: 10.1016/s0969-8051(02)00342-6.
Several radiopharmaceuticals and imaging techniques are proposed for breast cancer imaging. Since limited data are available of the uptake of SPECT and PET radiopharmaceuticals in malignant breast tumors and their metastases the aim of this study was to compare the uptake values and to correlate these data with imaging findings.
We have studied the uptake of F-18 FDG, Tc-99m MIBI and Tc-99m (V)DMSA in 31 tumors using immunosuppressed rats implanted with HH-16 clone 4 mammary tumor cells. Tumor gamma camera and PET imaging was performed to gain biokinetic data and uptake values by ROI-analysis.
Tumor uptake was highest for F-18 FDG > Tc-99m (V)DMSA > Tc-99m MIBI. The uptake ratios (tumor to muscle) correlated well with the ratios calculated by ROI-analysis determined by imaging.
In this in-vivo model, F-18 FDG revealed the best uptake and imaging properties and may be the radiopharmaceutical of choice for routine breast cancer imaging.
有几种放射性药物和成像技术被用于乳腺癌成像。由于关于单光子发射计算机断层扫描（SPECT）和正电子发射断层扫描（PET）放射性药物在恶性乳腺肿瘤及其转移灶中的摄取情况的数据有限，本研究的目的是比较摄取值，并将这些数据与成像结果相关联。
我们使用植入HH - 16克隆4乳腺肿瘤细胞的免疫抑制大鼠，研究了31个肿瘤中F - 18氟代脱氧葡萄糖（FDG）、锝 - 99m甲氧基异丁基异腈（MIBI）和锝 - 99m（V）二巯基丁二酸（DMSA）的摄取情况。通过肿瘤γ相机和PET成像，利用感兴趣区（ROI）分析获得生物动力学数据和摄取值。
肿瘤摄取情况为F - 18 FDG＞锝 - 99m（V）DMSA＞锝 - 99m MIBI。摄取率（肿瘤与肌肉）与通过成像确定的ROI分析计算出的比率相关性良好。
在这个体内模型中，F - 18 FDG显示出最佳的摄取和成像特性，可能是常规乳腺癌成像的首选放射性药物。
